Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0838 • ACR Convergence 2021
Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
Tawnie Braaten¹, shaobo Pei², Anitha Rathod², Gopi Penmetsa³, Kevin Douglas⁴, Jodi Walker⁴, Jerry Clewell⁵ and Jessica Walsh⁶, ¹Salt Lake City Veteran Affairs and University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., North Chicago, IL, ⁵Abbvie Inc, North Chicago, IL, ⁶Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Non-treatment and treatment delays contribute to suboptimal symptom control and irreversible joint damage in patients with inflammatory arthritis (IA). This investigations objective was to…
Abstract Number: 0919 • ACR Convergence 2021
Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
Kurt de Vlam¹, Philip Conaghan², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan⁵, Rebecca Bolce⁵, David Sandoval Calderon⁵, So Young Park⁵, Gaia Gallo⁵ and Walter Maksymowych⁶, ¹University Hospitals Leuven, Leuven, Belgium, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada
Background/Purpose: Ixekizumab (IXE) demonstrated rapid efficacy in patients (pts) with AS at week (W) 16 in the absence of elevated inflammation as measured by baseline…
Abstract Number: 1306 • ACR Convergence 2021
Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients
Laarni Quimson¹, Nisa Oren², Catherine Burns³ and Reem Jan², ¹University of Chicago, Oak Park, IL, ²University of Chicago, Chicago, IL, ³Indiana University, Indianapolis, IN
Background/Purpose: Inflammatory bowel disease (IBD) affects up to 1.3% of the population and is associated with musculoskeletal manifestations including spondyloarthritis (SpA). Axial SpA (axSpA) is…
Abstract Number: 0068 • ACR Convergence 2021
Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies
Nicholas Harvey¹, Jose Garrido-Mesa², Zhixiu Li³, David Evans⁴, Peter Sternes⁵ and Matthew Brown², ¹Molecular Genetics, London, United Kingdom, ²King's College London, London, United Kingdom, ³Queensland University of Technology, Brisbane, Australia, ⁴University of Queensland, Brisbane, Australia, ⁵Queensland University of Technology, Bisbane, Australia
Background/Purpose: There is strong evidence from animal models, human microbiome profiling studies, genetic analyses, and from the model of reactive arthritis, that AS is caused…
Abstract Number: 0382 • ACR Convergence 2021
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Carolina Tornero¹, Victoria Navarro-Compán², raquel almodovar³, Cristina fernández-Carballido⁴, Azucena Hernández⁵, Beatriz Joven-Ibáñez⁶, Xavier Juanola⁷, M.Lourdes Ladehesa-Pineda⁸, José Ramón maneiro⁹, Antoni Juan Mas¹⁰, carlos Montilla¹¹, Manuel J Moreno¹², Mireia moreno¹³, José A. pinto¹⁴, juan Carlos Quevedo¹⁵, José Rosas¹⁶, Teresa Ruiz¹⁷, Jesús Sanz¹⁸ and Eugenio De Miguel¹⁹, ¹University Hospital La Paz, Madrid, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Hospital Universitario Fundación de Alcorcón, Madrid, Spain, ⁴H. San Juan, Alicante, Alicante, Spain, ⁵Hospital Virgen de la Salud, Toledo, Spain, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ¹⁰Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹³Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain, ¹⁴Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ¹⁵Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, ¹⁷Hospital de Sierrallana, Servicio de Reumatología, Torrelavega, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁹Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Esperanza was a multicenter national health program developed to facilitate an early diagnosis of patients with Spondyloarthritis (SpA) in Spain. The main objective of…
Abstract Number: 0897 • ACR Convergence 2021
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Tae-Han Lee¹, Bon San Koo², Bora Nam³, Seunghun Lee⁴, Kyung Bin Joo⁴ and Tae-Hwan Kim³, ¹Keimyung University Dongsan Hospital, Daegu, Republic of Korea, ²Inje University Seoul Paik Hospital, Seoul, Republic of Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Hanyang University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
Abstract Number: 0920 • ACR Convergence 2021
Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
Filip Van den Bosch¹, Denis Poddubnyy², Jayne Stigler³, Andrew Ostor⁴, Salvatore D'Angelo⁵, Victoria Navarro-Compán⁶, In-Ho Song³, Tianming Gao³, Fabiana Ganz³ and Lianne Gensler⁷, ¹Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL, ⁴Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁵Rheumatology Institute of Lucania (IReL) – Rheumatology Department of Lucania, “San Carlo” Hospital of Potenza and “Madonna delle Grazie” Hospital of Matera, Potenza, Italy, ⁶Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁷Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has demonstrated efficacy and safety through 14 weeks in the SELECT-AXIS 1 study in biologic disease-modifying antirheumatic…
Abstract Number: 1314 • ACR Convergence 2021
Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis
Haluk Cinaklı¹, Elif Ediboglu¹, Eda Otman Akat², Dilek Solmaz³, Gulay Alp¹, Esra Erpek¹, Sercan Gücenmez⁴, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²katip çelebi, izmir, Turkey, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁴katip çelebi university, izmir, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute…
Abstract Number: 0139 • ACR Convergence 2021
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study
Alexis Ogdie-Beatty¹, Marina Magrey², Robert Fitzsimmons¹, Shahrzad Abdollahi¹, Ana Biljan³, Christopher Saffore⁴ and Jessica Walsh⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ³Abbvie Inc., Chicago, IL, ⁴AbbVie, North Chicago, IL, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: While recommendations for the treatment of ankylosing spondylitis (AS) are largely aligned across various guidelines,1,2 there remains variability in the treatment. Patients with inflammatory…
Abstract Number: 0383 • ACR Convergence 2021
Differences Between Male vs. Female Presenting with Back Pain in an Integrated Delivery System
Aniket Kawatkar¹, Esther Yi², Erika Estrada¹, Jose Pio¹, Cecilia Portugal¹, David Yi¹ and Steve Lee³, ¹Kaiser Permanente Southern California, Pasadena, CA, ²Novartis Pharmaceuticals Corporation, Weehawken, NJ, ³Southern California Permanente Medical Group, Fontana, CA
Background/Purpose: Back pain exerts significant economic burden and in its inflammatory form is the main clinical symptom of axial spondylarthritis. We evaluated differences in patient…
Abstract Number: 0899 • ACR Convergence 2021
Comparison of Sacroiliac CT Findings in Patients with and Without Ankylosing Spondylitis Aged 50 Years or Older: Preliminary Results of the CASIAGE Study
Olivier Fakih, Mickaël Chouk, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France
Background/Purpose: Diagnosis of axial spondyloarthritis (SpA) is nowadays commonly made with pelvic radiography or MRI. However, there is an important inter-observer variability for radiographs, and…
Abstract Number: 0922 • ACR Convergence 2021
Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Atul Deodhar¹, Maxime Dougados², Karl Gaffney³, Raj Sengupta⁴, Marina Magrey⁵, Natasha de Peyrecave⁶, Marga Oortgiesen⁷, Thomas Vaux⁸, Carmen Fleurinck⁶, Vanessa Taieb⁸, Christine de la Loge⁹ and Xenofon Baraliakos¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ³Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ⁴The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Slough, United Kingdom, ⁹PCOM Analytics, Avallon, France, Avallon, France, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 1318 • ACR Convergence 2021
Interplay Between Covid-19 and Spondyloarthritis or Its Treatment
Richard Howard¹, Michael Weisman², Hedley Hamilton³, Cassie Shafer¹, Elin Aslanyan¹, John Reveille⁴, Kevin Winthrop⁵, Dongseok Choi⁵, Kimbery Ogle⁵, Sarah Siegel⁵, Emily Papaspyru³, Donna Grims¹ and James T. Rosenbaum⁶, ¹Spondylitis Association of America, Encino, CA, ²Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Any-3, London, United Kingdom, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Oregon Health & Science University, Portland, OR, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: The Covid-19 pandemic has been especially challenging for patients with inflammatory diseases including spondyloarthritis (SpA). Patients with rheumatic and musculoskeletal diseases (RMDs) remain at…
Abstract Number: 0157 • ACR Convergence 2021
Development of a Deep Learning Algorithm for the Detection of Sacroiliitis on MRI in Patients with Active Axial Spondyloarthritis
Joeri Nicolaes¹, Pedro Machado², Xenofon Baraliakos³, Mayank Santosh⁴, Andrew Carnell⁴, Natasha de Peyrecave⁴ and Alexander Bennett⁵, ¹UCB Pharma, Brussels, Belgium; Medical Image Computing, ESAT-PSI, Department of Electrical Engineering, KU Leuven, Leuven, Belgium, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre Headley Court, Epsom, UK; National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom
Background/Purpose: Magnetic resonance imaging (MRI) plays a critical role in assisting the diagnosis of axial spondyloarthritis (axSpA). There are many characteristic MRI lesions that can…
Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Rouhin Sen¹, Emmeline Kim², Elizabeth Cheng³, Kavya Ganuthula⁴, Meika Fang⁵, Gail Kerr⁶, Jessica Walsh⁷, Elizabeth Chang⁸, Siba Raychaudhuri⁹, Andreas Reimold¹⁰ and Liron Caplan¹¹, ¹University of Colorado School of Medicine/Rocky Mountain Regional Veterans Affairs Medical Center (VAMC), Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ⁵David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁶Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, ⁹Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ¹⁰University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ¹¹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.